NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
Clinical Trials
10 trialsNCT06309615 2025-05-29
PDxBRUTILITY
Precise Dx, Inc.
Not yet recruiting
NCT06592222 2025-05-20
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Completed
NCT05236257 2024-12-10
EPI VITRAKVI
Bayer
Completed
NCT05932290 2024-10-29
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT05565391 2024-05-21
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT03501173 2023-07-25
GURC
Janssen Inc.
Completed
NCT02549222 2022-02-18
PIPER
Cerus Corporation
Completed
NCT03137264 2019-11-07
RADIANCE
AstraZeneca
Completed
NCT01254318 2016-11-02
TRAFIC
Merck Sharp & Dohme LLC
Completed